The FDA has approved PD-L1 IHC using a rabbit monoclonal antibody (clone 22C3), for selecting patients for the PD-1-blocking drug pembrolizumab in metastatic non-small-cell lung cancer [183], Ventana PD-L1 (SP263) assay for treatment of patients with locally advanced or metastatic urothelial carcinoma with anti-PD-L1 immunotherapy durvalumab, and Ventana PD-L1 (SP142) IHC assay for detecting PD-L1 expression in tumor-infiltrating immune cells. The gene discussed is CD274; the disease is neoplasm.